Improved Nanoparticle Based Targeted Drug Delivery to Cancerous Cells and Tissues

Back to all technologies

Bookmark/Download	Download as PDF
Track Code	2017-YEO-67767
Categories	Medical/Health Pharmaceuticals
Keywords	Cancer Cancer Therapy Drug Delivery Medical/Health Nanoparticles Pharmaceuticals
Public Abstract	Cancer is a group of diseases involving abnormal cell growth. Currently there are more than 100 types of identified cancer that affect human beings as well as animals. In 2016, there were an estimated 1,685,210 new human cancer cases diagnosed and 595,690 cancer deaths in the United States alone (Cancer Statistics 2016 - American Cancer Society, Inc.). Nanoparticles (NPs) have been considered a promising carrier of chemotherapeutic drugs, but are limited in delivery to tumors due to the diverse nature of the disease. There currently exists the need to leverage the enhanced permeability and retention effect to deliver NPs beyond the current levels possible. Researchers at Purdue University have developed a method for preparing polyol-modified nanoparticles for targeted delivery to cancerous cells and tissues via transcytosis across the peritumoral endothelium. This method does not depend on the leakiness of the vasculature like traditional nanoparticle formulations, but actively interacts with the vascular lining to enter tumors. Advantages: -Increases the amount of drugs deliver to solid tumors -Reduces the required dose and related side effects -Does not depend on long-term circulation and passive extravasation Potential Applications: -Cancer treatment -Drug delivery Related Publication: Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins Small 14 (50), 1803601 DOI: https://onlinelibrary.wiley.com/doi/full/10.1002/smll.201803601
People	Yeo, Yoon (Project leader) Xu, Jun
Intellectual Property	Application Date Jan 8, 2020 Type NATL-Patent Country of Filing China Patent Number (None) Issue Date (None) Application Date Dec 8, 2019 Type NATL-Patent Country of Filing Europe Patent Number (None) Issue Date (None) Application Date Nov 8, 2019 Type NATL-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date May 8, 2018 Type PCT-Patent Country of Filing WO Patent Number (None) Issue Date (None) Application Date May 8, 2018 Type NATL-Patent Country of Filing Canada Patent Number (None) Issue Date (None) Application Date May 8, 2018 Type NATL-Patent Country of Filing India Patent Number (None) Issue Date (None) Application Date May 8, 2018 Type NATL-Patent Country of Filing Japan Patent Number (None) Issue Date (None) Application Date May 8, 2017 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org